WO2019027810A1 - Wound therapy apparatus with scar modulation properties and related methods - Google Patents
Wound therapy apparatus with scar modulation properties and related methods Download PDFInfo
- Publication number
- WO2019027810A1 WO2019027810A1 PCT/US2018/043962 US2018043962W WO2019027810A1 WO 2019027810 A1 WO2019027810 A1 WO 2019027810A1 US 2018043962 W US2018043962 W US 2018043962W WO 2019027810 A1 WO2019027810 A1 WO 2019027810A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- distal
- distal layer
- layer
- wound
- pad
- Prior art date
Links
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 257
- 206010052428 Wound Diseases 0.000 title claims abstract description 255
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 38
- 231100000241 scar Toxicity 0.000 title description 12
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 49
- 210000000416 exudates and transudate Anatomy 0.000 claims abstract description 42
- 239000000463 material Substances 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 14
- -1 polysiloxanes Polymers 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 13
- 230000035876 healing Effects 0.000 claims description 13
- 238000004891 communication Methods 0.000 claims description 8
- 230000036573 scar formation Effects 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 239000010410 layer Substances 0.000 description 168
- 210000003491 skin Anatomy 0.000 description 34
- 239000000853 adhesive Substances 0.000 description 21
- 230000001070 adhesive effect Effects 0.000 description 21
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 13
- 239000004205 dimethyl polysiloxane Substances 0.000 description 12
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 12
- 229940008099 dimethicone Drugs 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 125000006850 spacer group Chemical group 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000002783 friction material Substances 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 241000284156 Clerodendrum quadriloculare Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920005830 Polyurethane Foam Polymers 0.000 description 2
- 229920002334 Spandex Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000003522 acrylic cement Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 229940057874 phenyl trimethicone Drugs 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011496 polyurethane foam Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000004759 spandex Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010048031 Wound dehiscence Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000023753 dehiscence Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229940100890 silver compound Drugs 0.000 description 1
- 150000003379 silver compounds Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A61F13/05—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive plasters or dressings
- A61F13/0203—Adhesive plasters or dressings having a fluid handling member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/74—Suction control
- A61M1/75—Intermittent or pulsating suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/77—Suction-irrigation systems
- A61M1/772—Suction-irrigation systems operating alternately
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/80—Suction pumps
- A61M1/82—Membrane pumps, e.g. bulbs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/84—Drainage tubes; Aspiration tips
- A61M1/85—Drainage tubes; Aspiration tips with gas or fluid supply means, e.g. for supplying rinsing fluids or anticoagulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/91—Suction aspects of the dressing
- A61M1/915—Constructional details of the pressure distribution manifold
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/91—Suction aspects of the dressing
- A61M1/918—Suction aspects of the dressing for multiple suction locations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/92—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with liquid supply means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/94—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with gas supply means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/96—Suction control thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00646—Medication patches, e.g. transcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/30—Gas therapy for therapeutic treatment of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
In various aspects, the wound therapy apparatus disclosed herein may include a distal layer to contact a wound bed, the distal layer comprised of silicone, and fenestrations disposed about the distal layer pass between a distal side of the distal layer and a proximal side of the distal layer to communicate between the distal side and the proximal side. A pad may cooperate with the proximal side of the distal layer to receive exudate communicated through the distal layer from the wound bed via the fenestrations, in various aspects. Various materials including medicament(s) may be communicated to the wound bed through the distal layer via the fenestrations, in various aspects. A structural member may be included, in various aspects, to secure the distal layer and pad to a skin surface, in various aspects. Methods of use of the wound therapy apparatus are disclosed herein.
Description
WOUND THERAPY APPARATUS WITH SCAR MODULATION PROPERTIES
AND RELATED METHODS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to United States Patent Application No. 15/663,708 filed 29 July 2017, United States Patent Application No. 15/663,709 filed 29 July 2017, United States Patent Application No.15/663,710 filed 29 July 2017, United States Patent Application No. 15/663,713 filed 29 July 2017, and United States Patent Application No.15/663,714 filed 29 July 2017. All of these applications to which priority is claimed are hereby incorporated by reference in their entirety herein.
BACKGROUND OF THE INVENTION
Field
[0002] This invention relates to medical devices, and more particularly, to wound therapy apparatus and related compositions of matter and methods of use.
Related Art
[0003] Wounds afflict hundreds of millions of people globally. Wounds are often traumatic, although the number of incisional wounds number over 71 million in the US. Many wounds heal with a scar that may be prominent, and, thus, stigmatize, affect esthetics, and diminish self-esteem. Hypertrophic scars such as keloids may limit function due to the thickness and restrictive nature of the scar tissue.
[0004] In order for an incisional wound to heal well and quickly with no visible or minimally visible scar formation, multiple important factors must be present, including adequate blood flow and oxygenation, absence of infection, proper moisture balance, even apposition (alignment) of wound edges with a homogenous dispersion of tension across the entire wound area. The classic ugly "railroad track" scar is typically caused by focal tension exerted by suture lines, which can be worsened yet further by a certain degree of wound dehiscence (wound edge separation). Silicone in the form of a sheet has been applied to the scar of a completely- or long-healed wound including keloids to induce collagen
reconfiguration with the therapeutic goal of a less prominent scar. The silicone sheet is a barrier to exudate transfer, and, therefore, by conventional wisdom, is not suitable for use during actual wound healing.
[0005] Similarly, while various dressing including bandages, covers, compresses, and so forth that are applied to wounds during healing are labeled as including silicone, the "silicone" label refers to the presence of a silicone (instead of, for example, an acrylic) adhesive that anchors the dressing to the skin surface. The silicone in these dressings, is not in direct contact with the wound, and because the silicone adhesive is easy to peel off the skin. These dressings take weeks or longer to work, and may be ineffective in mitigating scarring.
[0006] Accordingly, there is a need for improved apparatus as well as related methods for wound therapy that may, for example, reduce scarring while protecting the wound during the healing process.
BRIEF SUMMARY OF THE INVENTION
[0007] These and other needs and disadvantages may be overcome by the wound therapy apparatus and related methods of use disclosed herein. Additional improvements and advantages may be recognized by those of ordinary skill in the art upon study of the present disclosure.
[0008] In various aspects, the wound therapy apparatus disclosed herein may include a distal layer to contact a wound bed, the distal layer comprised of silicone, and fenestrations disposed about the distal layer pass between a distal side of the distal layer and a proximal side of the distal layer to communicate between the distal side and the proximal side. A pad may cooperate with the proximal side of the distal layer to receive exudate communicated through the distal layer from the wound bed via the fenestrations, in various aspects. Various materials including medicament(s) may be communicated to the wound bed through the distal layer via the fenestrations, in various aspects. A structural member may be included in various aspects to secure the distal layer and pad to a skin surface, in various aspects.
[0009] Methods of use of the wound therapy apparatus are disclosed herein. In various aspects, the methods of use may include the step of contacting a distal side of a distal layer of said wound therapy apparatus with a wound bed, the distal layer comprising silicone with fenestrations passing between the distal side of the distal layer and a proximal side of the distal layer. The methods of use may include the step of removing exudate from the wound bed by
communicating exudate from the distal side of the distal layer to the proximal side of the distal layer. The methods of use may include the step of moderating scar formation by contacting the wound bed with the distal layer comprising silicone throughout healing of the wound bed.
[0010] This summary is presented to provide a basic understanding of some aspects of the apparatus and methods disclosed herein as a prelude to the detailed description that follows below. Accordingly, this summary is not intended to identify key elements of the apparatus, methods, and compositions of matter disclosed herein or to delineate the scope thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1 A illustrates by perspective view an exemplary implementation of a wound therapy apparatus;
[0012] Figure IB illustrates by cross-sectional view through section 1A-1 A of the exemplary implementation of the wound therapy apparatus of Figure 1A;
[0013] Figure 1C illustrates by another perspective view the exemplary implementation of the wound therapy apparatus of Figure 1A;
[0014] Figure 2 illustrates by perspective view portions of the exemplary implementation of the wound therapy apparatus of Figure 1A;
[0015] Figure 3 illustrates by perspective view a second exemplary implementation of a wound therapy apparatus in exploded relation with a wound bed and skin surface;
[0016] Figure 4 illustrates by perspective view at least portions of a third exemplary implementation of a wound therapy apparatus;
[0017] Figure 5 illustrates by perspective view at least portions of a fourth exemplary implementation of a wound therapy apparatus;
[0018] Figure 6A illustrates by plan view at least portions of a fifth exemplary implementation of a wound therapy apparatus;
[0019] Figure 6B illustrates by cross-sectional view portions of the fifth exemplary implementation of a wound therapy apparatus of Figure 6A;
[0020] Figure 7A illustrates by cross-sectional view a sixth exemplary implementation of a wound therapy apparatus;
[0021] Figure 7B illustrates by cross-sectional view a seventh exemplary implementation of a wound therapy apparatus; and,
[0022] Figure 8 illustrates by perspective view at least portions of an eighth exemplary implementation of a wound therapy apparatus.
[0023] The Figures are exemplary only, and the implementations illustrated therein are selected to facilitate explanation. The number, position, relationship and dimensions of the elements shown in the Figures to form the various implementations described herein, as well as dimensions and dimensional proportions to conform to specific force, weight, strength, flow and similar requirements are explained herein or are understandable to a person of ordinary skill in the art upon study of this disclosure. Where used in the various Figures, the same numerals designate the same or similar elements. Furthermore, when the terms "top," "bottom," "right," "left," "forward," "rear," "first," "second," "inside," "outside," and similar terms are used, the terms should be understood in reference to the orientation of the implementations shown in the drawings and are utilized to facilitate description thereof. Use herein of relative terms such as generally, about, approximately, essentially, may be indicative of engineering, manufacturing, or scientific tolerances such as ±0.1%, ±1%, ±2.5%, ±5%, or other such tolerances, as would be recognized by those of ordinary skill in the art upon study of this disclosure.
DETAILED DESCRIPTION OF THE INVENTION
[0024] A wound therapy apparatus is disclosed herein. In various aspects, the wound therapy apparatus includes a distal layer that contacts a wound bed, the distal layer being comprised, at least in part, of silicone that may be generally in the form of a sheet. The wound bed may be in various states of healing ranging from a newly created wound bed to a wound bed that has nearly healed over. The distal layer includes fenestration that pass between a distal side of the distal layer that may contact the wound bed and a proximal side of the distal layer, in various aspects. A pad may cooperate with the fenestrations on the proximal side of the distal layer to absorb exudate communicated from the wound bed through the fenestrations or to communicate material(s) to the wound bed through the fenestrations, in various aspects.
[0025] In some aspects, the wound therapy apparatus includes a structural member that cooperates mechanically with the distal layer and with the pad, if present, and the structural member may be adhesively attachable to a skin surface around the wound bed to hold the distal layer in contact with the wound bed by an adhesive layer disposed about the structural member. The structural member may protect the wound bed, the distal layer, and the pad, when the pad
is present. The structural member may maintain the distal layer and the pad in relation to one another, in certain aspects.
[0026] Methods of use of the wound therapy apparatus are disclosed herein. In various aspects, the methods of use may include the step of contacting the distal side of the distal layer with an unhealed wound bed, the distal layer comprising silicone with fenestrations passing between the distal side of the distal layer and a proximal side of the distal layer, and the step of removing exudate from the wound bed by communicating exudate from the distal side of the distal layer to the proximal side of the distal layer. Methods of use of the wound therapy apparatus may include the step of moderating scar formation by exposing the wound bed to the distal layer comprising silicone, at least in part, and having fenestrations therethrough throughout healing of the wound bed. Methods of use of the wound therapy apparatus may include the step of intermittently replacing a wound interface throughout healing of the wound bed, the wound interface, in certain aspects, comprising the distal layer, the pad, and the structural member. Methods of use of the wound therapy apparatus may include the step of intermittently replacing the distal layer during healing of the wound bed.
[0027] Silicone, as used herein, includes siloxane, various polysiloxanes, silicone-like materials, and various combinations thereof that may be generally solid. Silicone may have the chemical formula [R2S1O];., where R is an organic group. Silicone may include, for example, silicone polymers having an average molecular weight in excess of 100,000 (e.g., between about 100,000 and about 10,000,000). Examples may include, but are not limited to, crosslinked siloxanes (e.g., crosslinked dimethicone or dimethicone derivatives), copolymers such as stearyl methyl-dimethyl siloxane copolymer, polysilicone-11 (a crosslinked silicone rubber formed by the reaction of vinyl terminated silicone and (methylhydro dimethyl)polysiloxane in the presence of cyclomethicone), cetearyl dimethicone/ vinyl dimethicone crosspolymer (a copolymer of cetearyl dimethicone crosslinked with vinyl dimethyl polysiloxane), dimethicone/phenyl vinyl dimethicone crosspolymer (a copolymer of dimethylpolysiloxane crosslinked with phenyl vinyl dimethylsiloxane), and dimethicone/vinyl dimethicone crosspolymer (a copolymer of dimethylpolysiloxane crosslinked with vinyl dimethyls iloxane) .
[0028] Fluid, as used herein, includes, liquid(s), gas(ses), and combinations thereof. In various aspects, material, as used herein, includes solid(s), liquid(s), and gas(ses), and material may include one or more medicament(s). Exudate, as used herein, includes, for example, proteinaceous liquids exuded from the wound bed, along with various plasma, blood and cellular components, and other liquids that may be exuded by the wound bed. Exudate may
also include other liquids such as perspiration from the skin surface surrounding the wound bed, other liquids as may be present on or about the wound bed or the skin surface proximate the wound bed. Exudate, as used herein, may include gas(ses) such as CO2 and water vapor exhaled from the skin surface.
[0029] In various aspects, the term fluid-tight or related terms, as used herein, means sufficiently leak-resistant to allow insufflation or vacuum suction to create pressure po that may be above or below ambient pressure pamb. The term fluid-tight means sufficiently leak-resistant to substantially retain fluids including both gasses and liquids within the enclosed space, in certain aspects. In certain aspects, fluid tight means sufficiently leak-resistant to maintain pressure po within the enclosed space that may be above or below ambient pressure pamb.
[0030] Wound bed, as used herein, means a focal breach in the external surface of normal skin, for example, from trauma (such as abrasion, avulsion, tearing, piercing, cutting, chemical or thermal injury) or microbial infection. The wound bed may include varying degrees of exposure of underlying layers and structures, along with possible infections and tissue changes. The wound bed represents an unhealed wound. In contrast, a healed wound is a skin surface that was previously injured but the focal breach is now entirely sealed and covered by varying amounts of epidermis and scar tissue.
[0031] As used herein the terms distal and proximal are relative, not necessarily absolute positional terms defined from the point of view of a caregiver, including physicians, nurses and technicians, treating a patient with the wound therapy apparatus. A distal portion of the wound therapy apparatus may be oriented toward the patient while a proximal portion of the wound therapy apparatus may be oriented toward the physician. When deployed, for example, a distal portion of the wound therapy apparatus may be closer to the patient while a proximal portion of the wound therapy apparatus may be closer to the caregiver. As a further example, a distal surface in a multi-layer wound interface is closer to the wound bed, but not necessarily the layer in contact with or closest to the wound bed.
[0032] Figures 1A, IB, 1C illustrates exemplary wound therapy apparatus 100. As illustrated in Figures 1A and IB, wound therapy apparatus 100 includes wound interface 115 secured to skin surface 111 to cover wound bed 113. Wound interface 115 includes structural member 120, pad 170, distal layer 180, and adhesive 190, as illustrated, and wound interface 115 is secured to skin surface 111 by adhesive 190.
[0033] Figure IB depicts cross-section IB-IB of Figure 1A with wound interface 115 illustrated as set apart from wound bed 113 and skin surface 111 for purposes of clarity of explanation, it should be understood that wound interface 115 is actually secured to skin surface
111. In this implementation, distal side 182 of distal layer 180 contacts wound bed 113 and adhesive 190 contacts skin surface 111 outside of wound boundary 112 of wound bed 113 so that there is no contact between adhesive 190 and wound bed 113 when wound interface is secured to skin surface 111.
[0034] As illustrated in Figure IB, pad 170 is interposed between structural member 120 and distal layer 180, distal side 172 of pad 170 is in biased engagement with proximal side 184 of distal layer 180, and proximal side 174 of pad 170 is faced toward distal side 122 of structural member 120. Pad 170 in biased engagement with distal layer 180 forms a combination structure 150, as illustrated in Fig. 1C. In some implementations, proximal side 174 of pad 170 may be secured to distal side 122 of structural member 120, while, in other implementations, proximal side 174 of pad 170 may be generally disposed about distal side 122 of structural member 120 but engaged with structural member 120 by engagement with distal layer 180 and not directly engaged with structural member 120. In this implementation, structural member 120, pad 170, and distal layer 180 are engaged with respect to one another in various ways, and structure 150 is secured to structural member 120 in various ways, as would be readily recognized by those of ordinary skill in the art upon study of this disclosure.
[0035] Structural member 120 may be, formed, for example, of a layer of polyurethane, fabric, polyethylene, polyvinyl chloride, or latex, and structural member 120 may be conformable to skin surface 111 proximate wound bed 113. In some implementations, structural member 120 and adhesive 190 have a suitable moisture- vapor transfer rate (MVTR) that allows for passage of O2, CO2, and water vapor from distal side 122 to proximal side 124 so that the skin surface 111 underneath may breathe, while generally excluding unwanted elements such as bacteria or water to protect wound bed 113 from external contamination. Although "breathable" in terms of transpiration, structural member 120 and adhesive 190 may be fluid tight as defined herein such that wound interface 115 is occlusive and usable for pressure therapy. Adhesive 190 may be formed, for example, of silicone based adhesive, acrylic, hydrocolloid, or other suitable medical adhesives. Adhesive 190 as a silicone based adhesive may have a lower tack than acrylic adhesive, and thus may be used when skin surface 111 is delicate or sensitive such as in neonates and the elderly to avoid damage to the skin surface 111 during removal of wound interface 115.
[0036] Because distal layer 180 is formed, at least in part, of silicone 135, in this implementation, distal layer 180 may not adhere to wound bed 113, for example, by adhesion of granulation tissues in wound bed 113 to distal side 182 of distal layer 180. In addition to such non-adhesion properties, the silicone 135 of distal layer 180 may modulate the expression
of two counteracting growth factors, fibroblast growth factor β (FGF β) and tumor growth factor β (TGF β) in wound bed 1 13. TGF β may stimulate fibroblasts to synthesize collagen and fibronectin. FGF β may normalize the collagen synthesis in wound bed 113 and may increases the level of collagenases that break down excess collagen. Distal layer 180 may thus restore the homeostatic balance of fibrogenesis and fibrolysis in wound bed 1 13. Distal layer 180 may increase hydration of stratum corneum, thereby facilitating regulation of fibroblast production and reduction in collagen production in wound bed 113. Such reversal of excessive collagen formation may result in a softer and flatter scar as wound bed 113 heals. The silicone 135 of distal layer 180 may reduce itching and discomfort associated with wound bed 1 13 as wound bed 1 13 heals.
[0037] Because silicone 135 has a high coefficient of friction, when wound bed 113 is formed as a linear wound, including an incisional wound that is at risk of dehiscence, distal layer 180 may aid in apposing the two sides of the linear wound together, thereby reducing the likelihood of healing by secondary intentions that would, in turn, result in a prominent wide scar. Distal layer 180 may provide additional benefits to wound bed 113 when contacted with wound bed 1 13, in various other implementations. Texture, such as texture 864 (see Figure 8), included on distal side 182 of distal layer 180 may increase the coefficient of friction of distal side 182 of distal layer 180.
[0038] As illustrated in Figure IB, distal layer 180 includes fenestrations 160 that extend between distal side 182 and proximal side 184 of distal layer 180 for communication between distal side 182 and proximal side 184 of distal layer 180. For example, exudate 118 exuded by wound bed 1 13 may be communicated from distal side 182 of distal layer 180 to proximal side 184 of distal layer 180 through fenestrations 160, for example, drawn by capillary action towards pad 170. Pad 170 then absorbs exudate 1 18 communicated from wound bed 113 through distal layer 180 via fenestrations 160. Accordingly, pad 170 prevents buildup of exudate 118 in wound bed 1 13 or on skin surface 1 11 and resultant maceration from prolonged contact with exudate 1 18. Material 1 16 such as air, oxygen, and medicament 176 may be communicated from pad 170 through fenestrations 160 from proximal side 184 to distal side 182 of distal layer 180 to wound bed 113, as illustrated in Figure IB. Material 1 16 may be communicated to wound bed 113 through fenestrations 160 by various transport mechanisms such as fluid flow, capillary action, and diffusion.
[0039] Fenestrations 160 may be sized in both quantity, distribution about distal layer, and aperture size to optimize transfer of exudate 1 18 from wound bed 113, for example, during different stages of healing of wound bed 1 13. For example, when wound bed 113 is formed as
an acute wound, exudate 1 18 from wound bed 1 13 may be thin (less viscous), and, thus, the fenestrations 160 may be relatively small. As another example, when wound bed 113 is formed as a chronic wound, exudate 118 from wound bed 113 may be more viscous, and, accordingly, fenestrations 160 may be larger or more plentiful.
[0040] Pad 170 may be formed, at least in part of, for example, polyvinyl alcohol, polyurethane foam, polyurethane foam with polyethylene glycol (PEG) that may enhance absorption and transport characteristics, gauze, fiber-like materials such as sodium carboxymethyl cellulose hydrofiber (Aquacel) or knitted synthetic fibers such as polypropylene and polyamide or a combination of both with hydrophobic polypropylene fiber predominant proximate distal side 172 and hydrophilic polyamide fibers predominant proximate proximal side 174 to conduct exudate 1 18 away from wound bed 1 13. An elastomeric fiber such as a polyester-polyurea (e.g., Spandex or Lycra) may additionally be incorporated in pad 170 to lend stretchability and conformability to pad 170.
[0041] Pad 170 may include various material(s) 116 including medicament(s) 176, such as, for example, antibiotics, analgesics such as local anesthetics, COX-2 inhibitors and nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, antimicrobial chitosan or silver compounds, bioactive factors such as the TGF-β superfamily; collagen synthesis inhibitors; cytokines, various formulations of placenta, including placental matrix powder, etc., for delivery to wound bed 113 through distal layer 180 via fenestrations 160. Pad 170 may include various indicator(s) 178 such as, for example, a florescent dye that indicates the pH under UV light thus indicating the health of the wound bed 1 13, and structural member may be formed, at least in part, of transparent or translucent material to allow viewing of the indicator. The materials that form pad 170 may be adjusted to accommodate such indicators or the delivery of medicament(s) 176 to the wound bed 113. Pad 170 may, for example, include multiple layers formed of differing materials or each of the multiple layers including various combinations of medicament(s) 176 or indicator(s) 178.
[0042] In certain implementations, medicament 178 as a liquid formulation may be pre- manufactured as a containment device adjacent to or connected to layer 170 and released by puncturing, removing or opening a partition in the containment device prior to applying wound interface 115 to wound bed 113. Alternatively, such separately containment devices may be added to or engaged with layer 170 prior to application of wound interface 115 via a syringe or via optional injection or intake ports.
[0043] As illustrated in Figure 1C, perimeter 153 of structure 150 is offset from edge 123 of structural member 120 by length 155 to prevent exposure of structure 150 when structural
member 120 is secured to skin surface 1 11. In other implementations, length 155 may be negligible so that perimeter 153 is coextensive with edge 123. Perimeter 153 of structure 150 may be offset from adhesive 190 by length 157. Length 157 may be selected to avoid contact between wound bed 113 and adhesive 190 when wound interface 1 15 is secured to skin surface 11 1 and distal layer 180 contacts wound bed 113.
[0044] As illustrated in Figure 1C, distal layer 180 and pad 170 of wound therapy apparatus 100 are coextensive with one another in structure 150, but this need not be the case in other implementations. Structural member 120 is illustrated as largely rectangular in shape with structure 150 disposed medially, and structure 150 is illustrated as having a rectangular shape. Structure 150 may be variously disposed about structural member 120, and structure 150 and structural member 120 may have various other geometric shapes, such as square, circular, oval, and the shapes of structural member 120 and structure 150 may be similar to one another or dissimilar from one another, in other implementations. Such other geometric shapes and dispositions may have equivalencies of lengths, such as lengths 155, 157, between a structure, such as structure 150, and an edge, such as edge 123, 193, as may be appropriate. For clarity of explanation, Figure 1 C, as well as the other Figures illustrative of wound therapy apparatus 100, does not show release liner layer(s) that may be included in various implementations of wound therapy apparatus 100, as would be readily recognized by those of ordinary skill in the art upon study of this disclosure.
[0045] Figure 2 illustrates distal layer 180 of exemplary wound therapy apparatus 100 including fenestrations 160 disposed about distal layer 180 that pass through distal layer 180 between distal side 182 and proximal side 184. Exudate 118 may be communicated between distal side 182 and proximal side 184 of distal layer 180 through the fenestrations 160 and material 1 16 may be communicated between proximal side 184 and distal side 182 of distal layer 180 through fenestrations 160. Fenestrations 160 in exemplary wound therapy apparatus 100 are illustrated as circular in geometry defining cylinders between proximal side 184 and distal side 182. Fenestrations, such as fenestrations 160, may have different shapes and sizes and may be distributed in regular and irregular patterns, in various implementations.
[0046] Thickness 187 of distal layer 180 may vary depending upon the type of wound bed 113 and degree of exudation with which wound interface 115 is employed. Thickness 187 may range from about 0.1 mm to about 2 mm, in certain implementations. Thickness 187 may range from about 0.2 mm to about 1 mm, in certain implementations. Distal side 182 may be flat or may include various textures, such as texture 864, as may depend upon the type of wound bed 113 with which wound interface 115 is employed. As thickness 187 increases, distal layer 180
may become less susceptible to stretch and distortion. In various implementations, the size of fenestrations 160 in distal layer 180 may generally range from about 250 microns to 2500 microns in diameter or equivalent, or from about 500 microns (#35 Mesh) to about 1000 microns (#18 Mesh) in diameter or equivalent. The number of fenestrations 160 in distal layer 180 per cm2 may range from about 25 per cm2 to about 200 per cm2, in certain implementations.
[0047] As illustrated in Figure 3, wound therapy apparatus 200 includes wound interface 215, and wound interface includes structural member 220, pad 270, and distal layer 280. Structural member 220, pad 270, and distal layer 280 are oblong in shape, and pad 270 is disposed between distal layer 280 and structural member 220, as illustrated. Border 223 of length 255 extends perimetrically around distal side 222 of structural member 220 to surround pad 270 in combination with distal layer 280. Adhesive, such as adhesive 190, 690, 790, disposed on at least portions of border 223 may secure wound interface 215 to skin surface 211 around wound bed 213. In some implementations of wound interface 215, structural member 220 is fluid tight and the adhesive sealingly secures wound interface 215 to the skin surface 211 around wound bed 213 to enclose pad 270 and distal layer 280, thereby forming an enclosed space 217 that is fluid tight over wound bed 213, i.e., wound interface 215 secured to skin surface 211 is occlusive. In such implementations, a port may be disposed about wound interface 215 for fluid communication through structural member 220 with enclosed space 217.
[0048] As illustrated in Figure 3, fenestrations 260 pass between distal side 282 and proximal side 284 of distal layer 280. Distal layer 280, in this implementation, is formed, at least in part of silicone 235. Fenestrations 260 disposed about distal layer 280 are illustrated as either square or star-burst shaped, and fenestrations 260 allow the communication of exudate 218, material 216, or both exudate 218 and material 216 between distal side 282 and proximal side 284 of distal layer 280, as illustrated.
[0049] As illustrated in Figure 3, window 227 formed of transparent or translucent material is disposed in structural member 220 between proximal side 224 and distal side 222. For example, window 227 may be formed of a polypropylene or polyethylene film that is sealed against a linear aperture within layer 220. A user may view at least portions of pad 270, for example, to determine a degree of saturation of pad 270 by exudate, such as exudate 218. As another example, an indicator, such as indicator 178, may be included in pad 270, and the indicator may be viewed through window 227, the indicator being indicative of the pH of pad 270, and, thus, indicative of conditions of wound bed 213.
[0050] Figure 4 illustrates distal layer 380 and pad 370 of exemplary wound therapy apparatus 300. Pad 370 conforms in shape to distal layer 380 with both pad 370 and distal
layer 380 being circular in shape, in this implementation. Pad 370 has distal side 372 and proximal side 374, and distal side 372 of pad 370 is secured to proximal side 384 of distal layer 380, as illustrated. Distal layer 380 is formed, at least in part, of silicone 335, and pad 370 may be formed of materials similar to those of pad 170 of exemplary wound therapy apparatus 100, in this implementation. Fenestrations 360 disposed about distal layer 380 pass between distal side 382 and proximal side 384 of distal layer 380, in this implementation. As illustrated in Figure 4, the fenestrations 360 are formed as Z-shaped slits. Note that fenestrations 360 decrease in size and increase in concentration within a central region of distal layer 380 within boundary 385 while fenestrations 360 are regularly sized and distributed outside boundary 385, as illustrated in Figure 4.
[0051] Figure 5 illustrates distal layer 480, which is formed, at least in part, of silicone 435, in exemplary wound therapy apparatus 400, and distal layer 480 including fenestrations 460 that pass between distal side 482 and proximal side 484 of distal layer 480 to allow communication of material 416 and exudate 418 between distal side 482 and proximal side 484. In Figure 5, distal layer 480 has an elongated rectangular shape, and fenestrations 460 are formed as star-burst shaped slits passing between distal side 482 and proximal side 484 of distal layer 480.
[0052] Figures 6A, 6B illustrate exemplary wound therapy apparatus 500 including distal layer 580 formed, at least in part, of silicone 535 and pad 570. As illustrated in Figure 6A, distal layer 580 is formed over the distal side 572 of pad 570, and distal layer 580 does not occlude the entire distal side 572 of pad 570. Distal layer 580 may be formed, for example, by rolling, spraying, or otherwise applying a layer of silicone material in pattern 587 over the distal side 572 of the pad 570 during manufacture. Various stencils, masks, screens, and so forth may be used to form pattern 587.
[0053] The silicone material may be, for example, silicone gel that may include one or more polysiloxanes, silicone dioxide, and a carrier formed of a volatile solvent, in various implementations. An example of a silicone gel is a dispersion of polysilicone-11 in phenyltrimethicone as carrier. Following application of the silicone gel to the distal side 572 of pad 570, the carrier, such as phenyltrimethicone, evaporates leaving the silicone 535 in place on distal side 572 of the pad 570 as distal layer 580 with pattern 587. The combined pad 570 and distal layer 580 then be die-cut and then assembled on the distal side of a structural member, such as structural member 120, 620, 720.
[0054] Figure 6A illustrates distal side 582 of distal layer 580. As illustrated in the detail of Figure 6A, distal layer 580 is formed, at least in part, of silicone 535 with pattern 587, and
pad 570 may be formed of materials similar to those of pad 170 of exemplary wound therapy apparatus 100. While pattern 587 is illustrated as generally of a regular rectangular geometry, pattern 587 may have various shapes, combinations of regularity and irregularity, and size distributions, in other implementations. Pattern 587 of distal layer 580 defines occluded regions 533 with fenestrations 560 between occluded regions 533 that expose distal side 572 of pad 570 to allow communication of exudate 518 or material 516 between distal side 582 and proximal side 584 of distal layer 580 and with distal side 572 of pad 570, as illustrated in Figures 6A, 6B. Thickness 589 of distal layer 580 may range from about 200 microns to about 1000 microns, in various implementations. Fenestrations 560 may range from about 50 microns (#270 Mesh) to about 1000 microns (#18 Mesh) in diameter or equivalent, or from about 100 microns (#140 Mesh) to about 750 microns (about #22 Mesh) in diameter or equivalent. The number of fenestrations 560 per cm2 may generally range from about 45 per cm2 to about 2500 per cm2, in various implementations.
[0055] Figure 7 A illustrates wound interface 615 of exemplary wound therapy apparatus 600 set apart from wound bed 613 and skin surface 61 1 for purposes of clarity of explanation. Wound bed 613 includes skin graft 615, in this implementation. Wound interface 615 includes distal layer 680 and pad 670 in cooperation with structural member 620 with pad 670 interposed between distal layer 680 and structural member 620. Distal layer 680 is formed, at least in part, of silicone 635, in this implementation. Adhesive 690 disposed about structural member 620 may affix structural member 620, and, thus, wound interface 615 to skin surface 611 to bias distal layer 680 against wound bed 613, in this implementation. Exudate 618 may be communicated through fenestrations 660 in proximal layer from wound bed 613 to pad 670, and material 616 may be communicated from pad 670 through fenestrations 660 to wound bed 613, as illustrated.
[0056] Shear force Fs is illustrated in Figure 7A as acting tangentially upon wound interface 615 of wound therapy apparatus 600. Shear force Fs may arise from various impacts having a tangential component upon wound interface 615 as may be incurred during the course of wearing of wound interface 615, for example, due to bumping on objects and interactions with clothing or bedding.
[0057] In the implementation of Figure 7 A, wound interface 615 includes spacer 640 having an envelope-like construction and located between adhesive 690, which is disposed over distal side 622 of structural member 620, and pad 670. In other implementations, spacer 640 may be located between structural member 620 and adhesive 690. Spacer 640 includes distal layer 642 and proximal layer 644, and distal layer 642 and proximal layer 644 define
space 646 in between, as illustrated. Spacer 640 may be formed as a film of a low-friction material 625 such as polyethylene or polypropylene for slideable engagement of proximal layer 644 with distal layer 642. The slideable engagement of proximal layer 644 with distal layer 642 in spacer 640 may at least partially deflect shear force Fs to reduce the transmission of shear force Fs to distal layer 680, and thence to wound bed 613. Proximal side 624 of structural member 620 may be formed of low friction material 625 in order to deflect shear force Fs, for example, to allow slippage between proximal side 624 and objects that contact proximal side 624. Accordingly, shear reducing means for reducing the transmission of shear force Fs to wound bed 613 may include spacer 640 having proximal layer 644 and distal layer 642 with space 646 therebetween, and the shear reducing means may include proximal side 624 of structural member 620 formed of low friction material 625.
[0058] Ab initio, the skin graft 615 is devoid of vascular connection. After a period of time, neovascular twigs begin to appear, reaching from the wound bed towards the skin graft 615 and ultimately establishing blood flow and viability of the graft. If the wound bed 613 including skin graft 615 is sheared during the vascularization period, the viability of the skin graft 615 is threatened. Thus, inclusion of spacer 640 or a low friction material 625 in proximal side 624 of structural member 620 may protect wound bed 613 including skin graft from disruption by shear force Fs by reducing of the transmission of shear force Fs to wound bed 613 or deflecting shear force Fs, respectively.
[0059] Figure 7B illustrates wound interface 715 of exemplary wound therapy apparatus 600 including pad 770 interposed between distal layer 780 and structural member 720. Wound interface 715 is illustrated as set apart from wound bed 713 and skin surface 71 1 for clarity of explanation. Distal layer 780 is formed, at least in part, of silicone 735, and distal layer 780 includes fenestrations 760 for the communication of exudate 718 and material 716 therethrough. Layer 742 is interposed between adhesive layer 790 and proximal side 774 of pad 770 with space 746 between layer 742 and proximal side 774 of pad 770, as illustrated. Layer 742 may be formed as a film of a low-friction material 725 such as polyethylene or polypropylene to facilitate slideable engagement between layer 742 and proximal side 774 of pad 770 that may reduce the transmission of shear force Fs applied to proximal side 724 of structural member to distal layer 780. As illustrated, layer 742 prevents adhesion of at least portions of pad 770 to structural member 720 by adhesive 790, and slideable engagement of layer 742 with proximal side 774 of pad allows movement between portions of structural member 720 and pad 770 to at least partially deflect shear force Fs applied to proximal side 724 of structural member 720. This may reduce the transmission of shear force Fs to wound
bed 713. In other implementations, for example, adhesive 790 may be omitted from portions of structural member 790 proximate proximal side 774 of pad 770 and layer 742 may be omitted so that at least portions of proximate proximal side 774 of pad 770 are slideably engaged with structural member 720 to allow movement between portions of structural member 720 and pad 770 that may least partially deflect shear force Fs applied to proximal side 724 of structural member 720. Accordingly, shear reducing means for reducing the transmission of shear force Fs to wound bed 713 may include, for example, layer 742 with space 746..
[0060] Figure 8 illustrates distal layer 880 of exemplary wound therapy apparatus 800, and distal layer 880 is formed, at least in part, of silicone 835. As illustrated in Figure 8, the fenestrations 860a, 860b, 860c, 860d, 860e, 860f passing between distal side 882 and proximal side 884 have a square, rectangular, starburst, circular, slit, and fish-mouthed geometries, respectively, and may be disposed about distal layer 880 in various fenestration patterns. Exudate 818 or material 816 may be communicated through fenestrations 860a, 860b, 860c, 860d, 860e, 860f between distal side 882 and proximal side 884. Geometry of fenestrations, such as fenestrations 860a, 860b, 860c, 860d, 860e, 860f, and fenestration patterns may be selected to preserve patency of the fenestrations during use that allows communication of exudate 818 or material 816 through the fenestrations. For example, fenestrations that are Z- shaped (e.g., fenestrations 360 in Figure 4) may be more likely to remain functionally patent than simple slits because the Z-shape may allow for more multidirectional stretching of the distal layer. Fish-mouthed fenestrations, such as fenestrations 860f, may also exhibit increased patency.
[0061] Figure 8 illustrates texture 864 on distal surface 882 of distal layer 880 that may be micro- or macro-surface textures in the form, for example, of bumps, pits, ridges, and combinations thereof. Texture 864 when biased against a wound bed, such as wound bed 113, 213, 613, 713 may cause micro-deformation and pressure points that may accelerate wound healing by stimulating cellular mitosis, differentiation, and angiogenesis.
[0062] As illustrated herein, the wound therapy apparatus, in some implementations, may include a distal layer, such as distal layer 180, 280, 680, 780, a pad, such as pad 170, 270, 670, 770, and a structural member, such as structural member 120, 220, 620, 720, as in wound therapy apparatus 100, 200, 600, 700. The wound therapy apparatus, in other implementations, may include a distal layer, such as distal layer 380, 580, and a pad, such as pad 370, 570, as in wound therapy apparatus 300, 500. The wound therapy apparatus, in yet other implementations, may include a distal layer, such as distal layer 480, as in wound therapy apparatus 400.
[0063] In various exemplary methods of operation, for example, a distal layer, such as distal layer 180, 280, 380, 480, 580, 680, 780, 880 of a wound therapy apparatus, such as wound therapy apparatus 100, 200, 300, 400, 500, 600, 700, 800 may be contacted with a wound bed, such as wound bed 113, 213, 613, for example, shortly after injury and before scar formation takes place. The distal layer, which is formed, at least in part, of silicone, such as silicone 135, 235, 335, 435, 535, 635, 735, 835, may provide an early homeostatic influence and may balance the collagen, fibronectin and collagenase levels in order to promote healing and reduce scarring that may obviate the protracted need for reversing excessive scarring after a scar had already formed.
[0064] In one exemplary method of operation, for example, the wound bed, which is unhealed, is contacted with the distal layer, which is formed, at least in part, of silicone, and the distal layer is employed essentially by itself with the pad, such as pad 170, 270, 370, 470, 570, 670, 770 and the structural member, such as structural member 120, 200, 620, 720 being omitted.
[0065] In another exemplary method of operation, the wound bed is contacted with the distal layer, and the distal layer is engaged with the pad, the structural member being omitted. In such exemplary methods of operation, the pad absorbs exudate, such as exudate 1 18, 218, 418, 518, 618, 818, communicated to the pad from the wound bed through fenestrations, such as fenestration 160, 260, 360, 460,560, 660, 760, 860a, 860b, 860c, 860d, 860e, 860f, in the distal layer. Material, such as material 116, 216, 416, 516, 616, 816, may be communicated to the wound bed through the fenestrations.
[0066] In a third exemplary method of operation, the wound bed is contacted with the distal layer, and the distal layer is engaged with the pad, and the structural member is deployed to cover the structure, such as structure 150, that includes the combination of distal layer with pad. The structural member may protect the pad, the distal member, or the pad in combination with the distal member, and the structural member may protect the wound bed.
[0067] In methods of operation that include the pad, the distal layer and the pad may be removed and then discarded when indicated, for example, when the pad is at least partly saturated with exudate. In some operations, a wound interface, such as wound interface 1 15, 215, 615, 715 may be removed and replaced with another wound interface that may be either similar to or dissimilar from the wound interface that was removed. Different wound interfaces may be used during the course of treatment of the wound bed, for example, as the amount of exudate exuded by the wound bed decreases or to deliver various medicaments, such as medicament 176, to the wound bed.
[0068] Various methods of operation may include delivery of the medicament to the wound bed through the distal layer from the pad. Various methods of operation may include contacting the wound bed with texture, such as texture 864, disposed about the distal side of the distal layer that may accelerate healing of the wound bed or may aid in apposition of the wound bed. Various methods of operation may include observing the pad through a window, such as window 227, disposed about the structural member. Various methods of operation may include observing an indicator, such as indicator 178, included in the pad, and the indicator may be observed through the window. Various methods of operation may include decreasing the shear force Fs transmitted though the wound interface to the wound bed. Various methods of operation may include removing exudate or fluid from the wound interface via one or more ports disposed about the wound interface, and may include inputting fluid into the wound interface via one or more ports disposed about the wound interface.
[0069] The foregoing discussion along with the Figures discloses and describes various exemplary implementations. These implementations are not meant to limit the scope of coverage, but, instead, to assist in understanding the context of the language used in this specification and in the claims. Upon study of this disclosure and the exemplary implementations herein, one of ordinary skill in the art may readily recognize that various changes, modifications and variations can be made thereto without departing from the spirit and scope of the inventions as defined in the following claims.
Claims
1. A wound therapy apparatus, comprising:
a distal layer to contact a wound bed, the distal layer comprised of silicone; and, fenestrations disposed about the distal layer that pass between a distal side of the distal layer and a proximal side of the distal layer to communicate between the distal side and the proximal side.
2. The apparatus of claim 1 , further comprising:
a pad disposed on the proximal side of the distal layer in cooperation with the fenestrations to absorbing exudate from the wound bed fluidly communicated through the fenestrations from the distal side of the distal layer to the proximal side of the distal layer.
3. The apparatus of claim 2, the pad comprising a hydrophobic material in fluid
cooperation with the proximal side of the distal layer to transfer exudate away from the proximal side of the distal layer and hydrophilic material in fluid cooperation with the hydrophobic material to absorb exudate from the hydrophobic material.
4. The apparatus of claim 1 , further comprising:
a pad comprising a medicament and disposed on the proximal side of the distal layer in cooperation with the fenestrations to communicate the medicament to the wound bed through the fenestrations.
5. The apparatus of claim 1 , further comprising:
a structural member engaged with the distal layer, the structural member adhesively securable to a skin surface about the wound bed to hold the distal layer in contact with the wound bed.
6. The apparatus of claim 5, further comprising:
a pad disposed on the proximal side of the distal layer in fluid communication with the fenestrations, the structural member being proximal of a proximal side of the pad.
7. The apparatus of claim 5, further comprising:
a window disposed in the structural member to allow observation through the structural member when the structural member is secured to the skin surface.
8. The apparatus of claim 5, further comprising:
at least one layer of low-friction film between the structural member and the distal layer to deflect at least a portion of shear force externally applied to the structural member.
9. A wound therapy apparatus, comprising:
a pad; and
a distal layer formed as a coating of silicone material on a distal surface of the pad that is non-occlusive in part to communicate exudate from a wound bed through non- occluded portions of the distal surface of the pad into the pad.
10. The apparatus of claim 9, further comprising:
a structural member engaged with the pad, the structural member adhesively securable to a skin surface about the wound bed to hold a distal side of the distal layer in contact with the wound bed.
1 1. The apparatus of claim 9, wherein the silicone material comprises a combination of one or more polysiloxanes and a carrier.
12. A method of use of a wound therapy apparatus comprising the steps of:
contacting a distal side of a distal layer of said wound therapy apparatus with a wound bed, the distal layer comprising silicone with fenestrations passing between the distal side of the distal layer and a proximal side of the distal layer; and
removing exudate from the wound bed by communicating exudate from the distal side of the distal layer to the proximal side of the distal layer.
13. The method of claim 12, the wound bed being unhealed.
14. The method of use of claim 12, further comprising the step of:
absorbing exudate within a pad cooperating with the distal side of the distal layer.
15. The method of use of claim 12, further comprising the step of:
delivering material to the wound bed by communicating the material from the proximal side of the distal layer to the distal side of the distal layer.
16. The method of use of claim 15, the material comprising a medicament.
17. The method of use of claim 12, further comprising the step of:
securing the distal layer in contact with the wound bed using a structural member adhesively attached to a skin surface about the wound bed, the structural member being in mechanical cooperation with the distal layer.
18. The method of use of claim 17, further comprising the step of:
forming the distal layer by selectively coating the distal side of the pad with silicone gel.
19. The method of use of claim 12, further comprising the step of:
replacing intermittently the wound therapy apparatus throughout healing of the wound bed.
20. The method of use of claim 12, further comprising the step of:
moderating scar formation by contacting the wound bed with the distal layer comprising silicone throughout healing of the wound bed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880049874.2A CN111343949A (en) | 2017-07-29 | 2018-07-26 | Wound treatment devices with scar modulating properties and related methods |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/663,709 | 2017-07-29 | ||
US15/663,714 US11712373B2 (en) | 2017-07-29 | 2017-07-29 | Wound therapy apparatus with scar modulation properties and related methods |
US15/663,710 | 2017-07-29 | ||
US15/663,714 | 2017-07-29 | ||
US15/663,713 US10729826B2 (en) | 2017-07-29 | 2017-07-29 | Wound cover apparatus and related methods of use |
US15/663,713 | 2017-07-29 | ||
US15/663,708 | 2017-07-29 | ||
US15/663,708 US11559622B2 (en) | 2017-07-29 | 2017-07-29 | Deformation resistant wound therapy apparatus and related methods of use |
US15/663,709 US20190030226A1 (en) | 2017-07-29 | 2017-07-29 | Augmented pressure therapy for wounds |
US15/663,710 US10780201B2 (en) | 2017-07-29 | 2017-07-29 | Control apparatus and related methods for wound therapy delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019027810A1 true WO2019027810A1 (en) | 2019-02-07 |
Family
ID=63165548
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/043959 WO2019027809A1 (en) | 2017-07-29 | 2018-07-26 | Wound cover apparatus and related methods of use |
PCT/US2018/043962 WO2019027810A1 (en) | 2017-07-29 | 2018-07-26 | Wound therapy apparatus with scar modulation properties and related methods |
PCT/US2018/043957 WO2019027808A1 (en) | 2017-07-29 | 2018-07-26 | Control apparatus and related methods for wound therapy delivery |
PCT/US2018/043955 WO2019027807A1 (en) | 2017-07-29 | 2018-07-26 | Augmented pressure therapy for wounds |
PCT/US2018/043953 WO2019027806A1 (en) | 2017-07-29 | 2018-07-26 | Deformation resistant wound therapy apparatus and related methods of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/043959 WO2019027809A1 (en) | 2017-07-29 | 2018-07-26 | Wound cover apparatus and related methods of use |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/043957 WO2019027808A1 (en) | 2017-07-29 | 2018-07-26 | Control apparatus and related methods for wound therapy delivery |
PCT/US2018/043955 WO2019027807A1 (en) | 2017-07-29 | 2018-07-26 | Augmented pressure therapy for wounds |
PCT/US2018/043953 WO2019027806A1 (en) | 2017-07-29 | 2018-07-26 | Deformation resistant wound therapy apparatus and related methods of use |
Country Status (2)
Country | Link |
---|---|
CN (5) | CN110944608B (en) |
WO (5) | WO2019027809A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10729826B2 (en) | 2017-07-29 | 2020-08-04 | Edward D. Lin | Wound cover apparatus and related methods of use |
US10780201B2 (en) | 2017-07-29 | 2020-09-22 | Edward D. Lin | Control apparatus and related methods for wound therapy delivery |
US11559622B2 (en) | 2017-07-29 | 2023-01-24 | Edward D. Lin | Deformation resistant wound therapy apparatus and related methods of use |
US11712373B2 (en) | 2017-07-29 | 2023-08-01 | Edward D. Lin | Wound therapy apparatus with scar modulation properties and related methods |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190351095A1 (en) * | 2018-05-21 | 2019-11-21 | Milliken & Company | Wound care device having fluid transfer and adhesive properties |
US20190351094A1 (en) * | 2018-05-21 | 2019-11-21 | Milliken & Company | Wound care device having fluid transfer and adhesive properties |
GB201917732D0 (en) * | 2019-12-04 | 2020-01-15 | Medtrade Products Ltd | Absorbent pads for wound dressings |
US11627970B2 (en) * | 2019-12-20 | 2023-04-18 | Merit Medical Systems, Inc. | Inflatable surgical compression device and related systems and methods |
CN112656563B (en) * | 2020-12-28 | 2022-07-01 | 吉林大学 | Permanent magnet umbilical protection belt for umbilical nursing of newborn |
CN113520720B (en) * | 2021-07-15 | 2022-09-30 | 上海美宝生命科技有限公司 | Closed negative pressure drainage dressing system |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110160686A1 (en) * | 2009-04-24 | 2011-06-30 | Alcare Co., Ltd. | Wound dressing and method for producing it |
GB2496310A (en) * | 2011-11-01 | 2013-05-08 | Brightwake Ltd | Yarn and textile material for wound dressings |
US20130231623A1 (en) * | 2012-03-05 | 2013-09-05 | Polyremedy, Inc. | Wound Dressing Inhibiting Lateral Diffusion Of Absorbed Exudate |
WO2015193257A1 (en) * | 2014-06-18 | 2015-12-23 | Smith & Nephew Plc | Wound dressing |
EP2995324A1 (en) * | 2014-09-11 | 2016-03-16 | Mölnlycke Health Care AB | Medical dressing |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2280915A (en) * | 1941-04-03 | 1942-04-28 | John H Johnson | Device for irrigating and treating wounds |
US7198046B1 (en) * | 1991-11-14 | 2007-04-03 | Wake Forest University Health Sciences | Wound treatment employing reduced pressure |
US5622725A (en) * | 1992-03-20 | 1997-04-22 | Alcide Corporation | Wound disinfection and repair |
US5522794A (en) * | 1994-06-16 | 1996-06-04 | Hercules Incorporated | Method of treating human wounds |
US6458109B1 (en) * | 1998-08-07 | 2002-10-01 | Hill-Rom Services, Inc. | Wound treatment apparatus |
US7842306B2 (en) * | 2003-08-14 | 2010-11-30 | Milliken & Company | Wound care device having fluid transfer properties |
GB0325129D0 (en) * | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus in situ |
GB0325120D0 (en) * | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus with actives |
GB0508529D0 (en) * | 2005-04-27 | 2005-06-01 | Smith & Nephew | Sai with microstress |
US10765785B2 (en) * | 2004-07-19 | 2020-09-08 | Thermotek, Inc. | Wound care and infusion method and system utilizing a therapeutic agent |
US7161056B2 (en) * | 2005-01-28 | 2007-01-09 | Ossur Hf | Wound dressing and method for manufacturing the same |
DK2010245T3 (en) * | 2005-11-21 | 2016-01-18 | Joshua David Smith | WOUND CARE SYSTEM |
JP2010512805A (en) * | 2006-08-30 | 2010-04-30 | サウス−イースタン メディカル テクノロジーズ | Methods, compositions and devices for treating wounds using pressures changed from atmospheric pressure |
US8357130B2 (en) * | 2006-11-21 | 2013-01-22 | Joshua David Smith | Wound care apparatus |
JP2010510837A (en) * | 2006-11-30 | 2010-04-08 | メデラ ホールディング アーゲー | Wound treatment device |
US8377016B2 (en) * | 2007-01-10 | 2013-02-19 | Wake Forest University Health Sciences | Apparatus and method for wound treatment employing periodic sub-atmospheric pressure |
SE531259C2 (en) * | 2007-06-27 | 2009-02-03 | Moelnlycke Health Care Ab | Device for treating reduced pressure ulcers |
US8152785B2 (en) * | 2008-03-13 | 2012-04-10 | Tyco Healthcare Group Lp | Vacuum port for vacuum wound therapy |
BRPI0912824B8 (en) * | 2008-05-21 | 2021-06-22 | Topaz Morris | wound healing device |
WO2013007973A2 (en) * | 2011-07-14 | 2013-01-17 | Smith & Nephew Plc | Wound dressing and method of treatment |
GB201108229D0 (en) * | 2011-05-17 | 2011-06-29 | Smith & Nephew | Tissue healing |
US8821419B1 (en) * | 2011-05-27 | 2014-09-02 | Allen L. Van Beek | Flexible interface external micro vacuum chamber tissue expander |
US9393354B2 (en) * | 2011-11-01 | 2016-07-19 | J&M Shuler Medical, Inc. | Mechanical wound therapy for sub-atmospheric wound care system |
EP2626049B1 (en) * | 2012-02-11 | 2018-07-25 | Paul Hartmann AG | Wound treatment device |
CA2864414C (en) * | 2012-02-13 | 2021-03-16 | Integrated Healing Technologies | Wound dressing apparatus |
EP2879635A2 (en) * | 2012-08-01 | 2015-06-10 | Smith & Nephew PLC | Wound dressing and method of treatment |
WO2014116783A1 (en) * | 2013-01-24 | 2014-07-31 | The Cleveland Clinic Foundation | Wound cover apparatus and method |
CN103071197A (en) * | 2013-01-29 | 2013-05-01 | 绍兴福清卫生用品有限公司 | Negative pressure wound dressing capable of flushing wound and using method for same |
AU2014266943B2 (en) * | 2013-05-10 | 2018-03-01 | Smith & Nephew Plc | Fluidic connector for irrigation and aspiration of wounds |
WO2015065616A1 (en) * | 2013-10-30 | 2015-05-07 | Kci Licensing, Inc. | Dressing with sealing and retention intereface |
US10245392B2 (en) * | 2014-08-08 | 2019-04-02 | Neogenix, Llc | Oxygen concentrating device, wound care apparatus, and treatment methods |
CN204723468U (en) * | 2015-06-23 | 2015-10-28 | 秦承雪 | A kind of skin wound treatment system for wound debridement, administration oxygen supply |
CN105369476B (en) * | 2015-10-09 | 2017-12-22 | 东华大学 | A kind of non-woven composite with directional water guiding function and preparation method thereof |
CN106730097A (en) * | 2016-12-23 | 2017-05-31 | 中南大学湘雅三医院 | A kind of hollow negative pressure drainage treatment system of alternating that hydrotherapy is circulated for surface of a wound debridement |
-
2018
- 2018-07-26 WO PCT/US2018/043959 patent/WO2019027809A1/en active Application Filing
- 2018-07-26 CN CN201880049910.5A patent/CN110944608B/en active Active
- 2018-07-26 WO PCT/US2018/043962 patent/WO2019027810A1/en active Application Filing
- 2018-07-26 WO PCT/US2018/043957 patent/WO2019027808A1/en active Application Filing
- 2018-07-26 WO PCT/US2018/043955 patent/WO2019027807A1/en active Application Filing
- 2018-07-26 CN CN201880049893.5A patent/CN110996866B/en active Active
- 2018-07-26 WO PCT/US2018/043953 patent/WO2019027806A1/en active Application Filing
- 2018-07-26 CN CN201880049874.2A patent/CN111343949A/en active Pending
- 2018-07-26 CN CN201880049890.1A patent/CN111050711B/en active Active
- 2018-07-26 CN CN201880049904.XA patent/CN110958866B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110160686A1 (en) * | 2009-04-24 | 2011-06-30 | Alcare Co., Ltd. | Wound dressing and method for producing it |
GB2496310A (en) * | 2011-11-01 | 2013-05-08 | Brightwake Ltd | Yarn and textile material for wound dressings |
US20130231623A1 (en) * | 2012-03-05 | 2013-09-05 | Polyremedy, Inc. | Wound Dressing Inhibiting Lateral Diffusion Of Absorbed Exudate |
WO2015193257A1 (en) * | 2014-06-18 | 2015-12-23 | Smith & Nephew Plc | Wound dressing |
EP2995324A1 (en) * | 2014-09-11 | 2016-03-16 | Mölnlycke Health Care AB | Medical dressing |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10729826B2 (en) | 2017-07-29 | 2020-08-04 | Edward D. Lin | Wound cover apparatus and related methods of use |
US10780201B2 (en) | 2017-07-29 | 2020-09-22 | Edward D. Lin | Control apparatus and related methods for wound therapy delivery |
US11559622B2 (en) | 2017-07-29 | 2023-01-24 | Edward D. Lin | Deformation resistant wound therapy apparatus and related methods of use |
US11712373B2 (en) | 2017-07-29 | 2023-08-01 | Edward D. Lin | Wound therapy apparatus with scar modulation properties and related methods |
Also Published As
Publication number | Publication date |
---|---|
CN110944608A (en) | 2020-03-31 |
CN111050711A (en) | 2020-04-21 |
CN111050711B (en) | 2022-05-27 |
CN110996866B (en) | 2023-06-02 |
CN110996866A (en) | 2020-04-10 |
CN110944608B (en) | 2022-07-26 |
CN111343949A (en) | 2020-06-26 |
WO2019027807A1 (en) | 2019-02-07 |
CN110958866A (en) | 2020-04-03 |
WO2019027809A1 (en) | 2019-02-07 |
CN110958866B (en) | 2022-07-19 |
WO2019027806A1 (en) | 2019-02-07 |
WO2019027808A1 (en) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019027810A1 (en) | Wound therapy apparatus with scar modulation properties and related methods | |
US11806215B2 (en) | Apparatus for wound therapy | |
US11712373B2 (en) | Wound therapy apparatus with scar modulation properties and related methods | |
US8269059B2 (en) | Protective dressing and methods of use thereof | |
RU2603714C2 (en) | Tissue healing | |
US10201631B2 (en) | Wound management system and methods of using | |
JP6838812B2 (en) | Negative pressure wound dressing with absorbent adhesive sealant layer | |
US5025783A (en) | Method of applying a medical dressing device | |
ES2333490T3 (en) | BETTER IMPROVED FOR WOUNDS. | |
EP3050545B1 (en) | Conformable medical dressing with self supporting substrate | |
US20180200417A1 (en) | Suction disc | |
US4730611A (en) | Medical dressing device | |
US20080103489A1 (en) | Vacuum adherent dressings, systems and methods of use for same | |
NO324890B1 (en) | Bandage and epidermal positioning mechanism and method of using the same | |
Thomas | Atraumatic dressings | |
US20190030225A1 (en) | Deformation resistant wound therapy apparatus and related methods of use | |
Thomas | A structured approach to the selection of dressings | |
Hess | Product guide to skin & wound care | |
Tan et al. | A comparison of ZenodermR with DuoDERM ER in the treatment of split skin graft donor sites | |
WO2002102425A2 (en) | Compound hydrogel wound dressing | |
KR200359390Y1 (en) | A medical patch | |
Spottheim | Medical dressing | |
CN220860391U (en) | Sterile biological wound protection film for wound healing | |
Wong et al. | Surgical Dressings | |
Beldon | Skin grafts 2: management of donor site wounds in the community |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18752999 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18752999 Country of ref document: EP Kind code of ref document: A1 |